Zacks.com on MSN6d
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...
Hosted on MSN4d
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...
Cure Today1d
FDA Grants Breakthrough Therapy Designation to Trodelvy for Small Cell Lung Cancer
The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...
pharmaphorum4d
ASCO22: Gilead makes case for Trodelvy in advanced breast cancer
In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.
The Pharma Letter7d
FDA Breakthrough status for Trodelvy in ES-SCLC
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...
FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...
Gilead granted Breakthrough Therapy Designation for Trodelvy by FDA
Gilead (GILD) announced that the FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with ...
Gilead and Terray link to develop small-molecule therapies
In September 2024, Gilead announced a strategic partnership with Genesis Therapeutics, focusing on AI to discover and develop ...
Daily5d
Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy
Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...
Nasdaq4d
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
Gilead’s oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified the company’s overall business. However, the Cell Therapy franchise ...